Ovid Therapeutics (1OT) Stock Statistics & Valuation Metrics
Total Valuation
Ovid Therapeutics has a market cap or net worth of EUR 442.68M. The enterprise value is EUR 426.65M.
- Market Cap
- EUR 442.68M
- Enterprise Value
- EUR 426.65M
Share Statistics
Ovid Therapeutics has 195,297,850 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 195,297,850
- Owned by Insiders
- 6.72%
- Owned by Institutions
- 21.36%
Financial Efficiency
Ovid Therapeutics’s return on equity (ROE) is -0.13 and return on invested capital (ROIC) is -29.46%.
- Return on Equity (ROE)
- -0.13
- Return on Assets (ROA)
- -0.12
- Return on Invested Capital (ROIC)
- -29.46%
- Return on Capital Employed (ROCE)
- -0.30
- Revenue Per Employee
- 315.30K
- Profits Per Employee
- -757.13K
- Employee Count
- 23
- Asset Turnover
- 0.05
- Inventory Turnover
- 0.00
Valuation Ratios
The current PE Ratio of Ovid Therapeutics is -5.29. Ovid Therapeutics’s PEG ratio is 0.15.
- PE Ratio
- -5.29
- PS Ratio
- 313.36
- PB Ratio
- 0.89
- Price to FCF
- -9.06
- Price to Operating Cash Flow
- -3.42
- PEG Ratio
- 0.15
Income Statement
In the last 12 months, Ovid Therapeutics had revenue of 7.25M and earned -17.41M in profits. Earnings per share was -0.24.
- Revenue
- 7.25M
- Gross Profit
- 6.95M
- Operating Income
- -42.44M
- Pretax Income
- -17.41M
- Net Income
- -17.41M
- EBITDA
- -17.14M
- Earnings Per Share (EPS)
- -0.24
Cash Flow
In the last 12 months, operating cash flow was -54.77M and capital expenditures 0, giving a free cash flow of -54.77M billion.
- Operating Cash Flow
- -54.77M
- Free Cash Flow
- -54.77M
- Free Cash Flow per Share
- -0.74
Dividends & Yields
Ovid Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- -11.04%
- Earnings Yield
- -18.42%
Stock Price Statistics
- Beta
- 1.18
- 52-Week Price Change
- 88.24%
- 50-Day Moving Average
- 2.20
- 200-Day Moving Average
- 2.01
- Relative Strength Index (RSI)
- 55.53
- Average Volume (3m)
- 50
Important Dates
Ovid Therapeutics upcoming earnings date is Nov 11, 2026, TBA (Not Confirmed).
- Last Earnings Date
- Aug 13, 2026
- Next Earnings Date
- Nov 11, 2026
- Ex-Dividend Date
- ―
Financial Position
Ovid Therapeutics as a current ratio of 10.91, with Debt / Equity ratio of 10.27%
- Current Ratio
- 10.91
- Quick Ratio
- 10.91
- Debt to Market Cap
- 0.00
- Net Debt to EBITDA
- -0.02
- Interest Coverage Ratio
- 0.00
Taxes
In the past 12 months, Ovid Therapeutics has paid 0 in taxes.
- Income Tax
- 0
- Effective Tax Rate
- 0.00
Enterprise Valuation
Ovid Therapeutics EV to EBITDA ratio is -13.95, with an EV/FCF ratio of -9.08.
- EV to Sales
- 314.24
- EV to EBITDA
- -13.95
- EV to Free Cash Flow
- -9.08
- EV to Operating Cash Flow
- -9.08
Balance Sheet
Ovid Therapeutics has EUR 117.22M in cash and marketable securities with EUR 12.71M in debt, giving a net cash position of EUR 104.50M billion.
- Cash & Marketable Securities
- EUR 117.22M
- Total Debt
- EUR 12.71M
- Net Cash
- EUR 104.50M
- Net Cash Per Share
- EUR 0.54
- Tangible Book Value Per Share
- EUR 2.85
Margins
Gross margin is 100.00%, with operating margin of -3686.67%, and net profit margin of -2178.90%.
- Gross Margin
- 100.00%
- Operating Margin
- -3686.67%
- Pretax Margin
- -2178.90%
- Net Profit Margin
- -2178.90%
- EBITDA Margin
- -2252.37%
- EBIT Margin
- -2257.68%
Analyst Forecast
The average price target for Ovid Therapeutics is EUR 5.80, which is 11.43% higher than the current price. The consensus rating is Strong Buy
- Price Target
- EUR 5.80
- Price Target Upside
- 158.96% Upside
- Analyst Consensus
- Strong Buy
- Analyst Count
- 10
- Revenue Growth Forecast
- -76.89%
- EPS Growth Forecast
- 56.40%
Scores
- Smart Score
- 6
- AI Score
- ―